New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
11:54 EDTICPTIntercept rises 14% to $343.49 as trial link circulated
Shares of Intercept Pharmaceuticals (ICPT) are significantly higher in late morning trading, with the move up potentially related to the circulation of a link to data on a clinical trial being run by Intercept for its study to test Obeticholic Acid's effectiveness when used in patients with moderately severe alcoholic hepatitis. The trial was initially posted to the government's ClinicalTrials.gov website in January, though it is unclear if new data has been made available via the site or otherwise. Reference Link
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use